The global kinase inhibitors market reached $28.1 billion in 2010 and nearly $29.1 billion in 2011. The market is expected to reach $40.2 billion by 2016, a compound annual growth rate (CAGR) of 6.7%.
The Asian market for kinase inhibitors reached $5.2 billion in 2010 and came down to $5.0 billion in 2011. The market is expected to decrease to $8.5 billion by 2016, a CAGR of 11.0%.
The antibody segment in Asia reached $3.4 billion in 2010 and came down to $3.0 billion in 2011. The segment is expected to reach $4.6 billion by 2016, a CAGR of 9.1%.
GLOBAL REVENUE OF KINASE INHIBITORS MARKET, 2009-2016
Source: BCC Research
BCC's goal in conducting this study is to provide an overview of the current and future characteristics of the global market for kinase inhibitors. The key objective is to present a comprehensive analysis and the future direction of kinase inhibitors to provide an important tool for the usage of these types of enzyme inhibitors.
This report explores present and future strategies within the kinase inhibitors market, which includes tyrosine inhibitors, multi-target kinase inhibitors, serine/ threonine inhibitors and monoclonal antibody kinase inhibitors. The direction of the market, its setbacks and the needs of the market are discussed in this report. The classifications, comparisons and usage of these types of enzyme inhibitors are also examined in the report.
A detailed analysis of the kinase inhibitors industry structure has been conducted. Revenues are broken down by region. Sales figures are estimated for the five-year period from 2011 through 2016.
Applications for kinase inhibitors are also discussed separately in the report, with emphasis on the usage of the inhibitors in therapeutic categories and various disease sectors. The report also covers significant patents and a summary of patents awarded in each category.
Extensive research in the field of kinase inhibitors has revealed their target-specific functionality in being able to provide therapeutic treatments for various chronic diseases. Modern industries have now begun to explore the advantages of kinase inhibitors in their productions and processes. This has led to the steady market for them.
R&D spending along with increasing competition, patent expiries and new technologies are directing kinase inhibitors to new directions. The new advancements, new product launches and the changing lifestyle have influenced the market to grow in the foreseeable future. This study looks at almost all the systems affected by these factors.
Acquisition strategies and collaborations by companies are also covered in this report. This study also discusses the strengths and weaknesses of each type/ technology in light of the new technologies, growing competition and changing customer needs.
A team of professionals in the biotechnology industry carried out this study. The project manager is Shalini S. Dewan, who holds a master's degree in pharmaceutical chemistry and has over 14 years of industry experience. Among the research topics she has covered are studies on compounds of potential pharmaceutical interest from ibuprofen and 2-naphthyl acetic acid. Shalini was awarded a Gold Medal by the Prime Minister of India for her work and has worked with top companies in India and in the U.S.